| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.07 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.053 | 0.08 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.08 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.08 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.06 | 0.08 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.08 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.09 | 0.09 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.057 | 0.09 |